We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Three Genes Linked to the Inheritance of Crohn’s Disease Identified

By LabMedica International staff writers
Posted on 29 Dec 2011
An advanced gene mapping technique has revealed the location of three genes on chromosome 16 linked to the inheritance of Crohn’s Disease (CD) that are in near proximately to the gene for nucleotide-binding oligomerization domain-containing protein 2 (NOD2), a known CD causative agent.

Crohn’s Disease is a chronic inflammatory disease caused by interactions between environmental, immunological, and bacterial factors that usually affects the ileum and colon, and frequently runs in families. More...
The inflamed lesions are rich in inflammatory cytokines, particularly interleukins -1, -6, and -12 and tumor necrosis factor alpha.

Homozygosity for a mutation in NOD2 increases the risk of the disease by a factor of 20 to 40. NOD2 encodes an intracellular protein that contains two caspase-recruitment domains, a nucleotide-binding domain, and 10 leucine-rich sequence repeats in the C-terminal region.

In the current study, investigators at University College London (United Kingdom) sought additional genetic markers that would help predict the likelihood of developing CD. Towards this end they used an advanced gene mapping technique called linkage disequilibrium mapping (LDM) to analyze samples from 1698 CD patients maintained by the Wellcome Trust Case Control Consortium and from 813 patients provided by the US National Institute of Diabetes and Digestive and Kidney Diseases.

Results published in the December 9, 2011, edition of the American Journal of Human Genetics revealed the identification of three novel genes, CYLD, IRF8, and CDH1/CDH3, associated with CD and involved with inflammation and immune system malfunction.

Senior author Dr. Nikolas Maniatis, professor of genetics at University College of London, said, “This project essentially maps the most likely location of faulty sites for Crohn's Disease in the genome. By combining several pieces of information together, our technique lets us increase the power of our analysis. These are very exciting times, as we can use these genetic maps to pinpoint where the causal sites of Crohn's Disease are located. Although it has been shown in the past that a proportion of patients suffering from Crohn's Disease do not carry the NOD2 mutations, up until now no other genes on chromosome 16 have been published in genome-wide analyses.”

“This paper shows how personalized medicine could work and also help to separate out patients. For example, just as there are many different types of cancer with different underlying genes, it seems that there are also mutations in different genes for different types of Crohn's Disease,” said Dr. Maniatis.

Related Links:
University College London



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.